What if everything we thought we knew about ‘immune cold’ breast cancers is wrong? This was one of…
When resistance and toxicities collide, the inevitable fallout is more likely
What's looking interesting in early stage trials at ASCO24?
A discussion of some of the key topics emerging in ER+ HER2- breast cancer
PARP inhibitors move into the adjuvant setting at long last? Say it ain't so!
Some key learnings from the ESMO Breast Cancer meeting held last week
Highlights from various breast cancer trials and new pipeline developments
There are a few new developments of note to consider from ESMO Breast this weekend plus more to come at ASCO20 on Friday
An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer
Review of 4 noteworthy posters at the 2016 European Breast Cancer Conference in Amsterdam organised by European Cancer Organisation ECCO
